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Stereotactic Body 
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Stage I NSCLC
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Evidence-Based 
Medicine
In Response:
We thank Dr. Barlett for his 
encouraging comment on our arti-
cle.1 In the current European Society 
for Medical Oncology (ESMO)2 and 
National Comprehensive Cancer 
Network (NCCN) V 2.2013 guide-
lines, stereotactic body radiotherapy 
(SBRT) is the recommended standard 
of care for patients with stage I non–
small-cell lung cancer, who are inoper-
able because of medical comorbidities. 
Robust outcome in a multi-institu-
tional environment despite variability 
in technical details of planning and 
delivery is a prerequisite for safe and 
effective guideline-compliant SBRT 
practice on a population-based level. 
Our results therefore support two pop-
ulation-based analyses, which reported 
an improvement in overall survival for 
stage I non–small-cell lung cancer in 
the elderly patient population by the 
implementation of SBRT,3,4 providing 
high level of evidence.
Lobectomy is the accepted stan-
dard of care for operable patients. The 
achievements of high local tumor con-
trol and favorable overall survival in a 
prognostic unfavorable patient popu-
lation resulted in a transfer of SBRT 
practice to fitter, healthier patients, who 
refused surgical resection. Retrospective 
studies described outcome approaching 
surgical results, indicating that overall 
survival after SBRT is mainly com-
promised by age and comorbidities of 
the patients and not by inferior onco-
logical efficacy compared with surgi-
cal resection.5,6 On the basis of these 
To the Editor:
I am writing with regard to 
Guckenberger et al.’s1 article relating 
the safety and efficacy of stereotactic 
body radiotherapy (SBR) for stage 1 
non–small-cell lung cancer in routine 
clinical practice.
I agree this is an important 
therapy that requires continual 
review to elucidate optimal therapeu-
tic delivery for efficacy and safety 
concerns and am encouraged by the 
consistency reported by other studies 
of the overall 3-year survival of 48% 
patients.2
There is temptation to compare 
SBR with surgery in the potentially 
fit patient. A recent review of the 
U.K. experience in surgical resec-
tion of lung cancer by Powell et al.3 
may provide a robust comparison of 
the safety of the surgical alternative 
which in no cohort, other than racial, 
achieved a safety equivalent to SBR. 
The cohort of stage 1A NSCLC 
patients had 30- and 90-day mortal-
ity rate at 1.6% and 3.4%, respec-
tively. This is significantly worse 
than SBR, despite being an intrinsi-
cally fitter population by virtue of 
being offered surgery. Is it time to 
usurp the surgeon?
Overall survival is the last 
remaining issue to determine whether 
SBR has a broader role. Alexander 
et al.4 have attempted to compare 
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SABR with surgery in elderly patients, 
however, their study was limited by a 
lack of age matching of the cohort 
and the use of sublobar resections. An 
important, age-matched retrospective 
review by Varlotto et al.5 suggests 
little difference in efficacy of surgery 
or SBR.
With the technical insights 
garnered from Guckenberger et al.’s 
review1 we are at clinical equipoise 
and await results of current, pro-
spective randomized trials free of 
selection bias. In the interim, which 
is likely to be prolonged, a frank 
and open discussion of the options 
with patients is required. At the 
very least, the former apathy toward 
management of elderly patients 
with early-stage lung cancer must 
be revoked in light of a safe, eff ica-
cious, and low-burden therapy such 
as SBR seems to be.
James Bartlett, MBBS
Western Hospital
Melbourne, Australia 
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